6 news items
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
VKTX
4 Jun 24
the U.S. In addition, following the completion of the call, a telephone replay will be accessible until
Viking Therapeutics to Participate at Upcoming Investor Conferences
VKTX
30 May 24
, Lyon, FranceA live webcast of the Jefferies presentations may be accessed via a link
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
VKTX
24 Apr 24
from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
ATNM
AZN
BMY
18 Apr 24
BMT access and engagement. Click HERE to read more
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
VKTX
17 Apr 24
the U.S. In addition, following the completion of the call, a telephone replay will be accessible until
oum4d9anr35x
VKTX
26 Mar 24
the completion of the call, a telephone replay will be accessible until April 2, 2024
- Prev
- 1
- Next